Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance).

Autor: Walker AR; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.; The Ohio State University Comprehensive Cancer Center, Columbus, OH., Marcucci G; Gehr Family Center for Leukemia Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA., Yin J; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN., Blum W; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA., Stock W; University of Chicago Comprehensive Cancer Center, Chicago, IL., Kohlschmidt J; Clara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus, OH.; Alliance Statistics and Data Center, The Ohio State University, Columbus, OH., Mrózek K; Clara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Carroll AJ; Department of Genetics, University of Alabama at Birmingham, Birmingham, AL., Eisfeld AK; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.; Clara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Wang ES; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY., Jacobson S; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN., Kolitz JE; Department of Medicine, Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY., Thakuri M; Southeast Clinical Oncology Research Consortium, National Cancer Institute Community Oncology Research Program, Cancer Care of Western North Carolina, Asheville, NC., Sutamtewagul G; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA., Vij R; Division of Hematology and Oncology, Washington University School of Medicine, St Louis, MO., Stuart RK; Department of Medicine, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; and., Byrd JC; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.; The Ohio State University Comprehensive Cancer Center, Columbus, OH., Bloomfield CD; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.; The Ohio State University Comprehensive Cancer Center, Columbus, OH., Stone RM; Department of Medical Oncology, Dana-Farber/Partners CancerCare, Boston, MA., Larson RA; University of Chicago Comprehensive Cancer Center, Chicago, IL.

Publikováno v: Blood advances [Blood Adv] 2021 Jul 13; Vol. 5 (13), pp. 2775-2787.

Multiple mechanisms contribute to acquired TRAIL resistance in multiple myeloma.

Autor: Ticona-Pérez, Fany V.¹ (AUTHOR), Chen, Xi¹ (AUTHOR), Pandiella, Atanasio^1,2,3 (AUTHOR) atanasio@usal.es, Díaz-Rodríguez, Elena^1,2,3,4 (AUTHOR) ediaz@usal.es

Publikováno v: Cancer Cell International. 8/5/2024, Vol. 24 Issue 1, p1-15. 15p.

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.

Autor: Durie BGM; Cedars-Sinai Samuel Oschin Cancer Center, Los Angeles, CA, USA. Electronic address: bdurie@myeloma.org., Hoering A; Cancer Research and Biostatistics, Seattle, WA, USA., Abidi MH; Spectrum Health Cancer Center, Michigan State University, Grand Rapids, MI, USA., Rajkumar SV; Mayo Clinic, Rochester, MN, USA., Epstein J; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA., Kahanic SP; Siouxland Regional Cancer Center, Sanford NCORP of the Northern Central Plains, Sioux City, IA, USA., Thakuri M; Southeast Clinical Oncology Research Consortium NCORP, Cancer Care of Western North Carolina, Asheville, NC, USA., Reu F; Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA., Reynolds CM; Michigan Cancer Research Consortium NCORP, St Joseph Mercy Hospital, Ann Arbor, MI, USA., Sexton R; Cancer Research and Biostatistics, Seattle, WA, USA., Orlowski RZ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Barlogie B; Myeloma Program, Mount Sinai School of Medicine, New York, NY, USA., Dispenzieri A; Division of Hematology, Mayo Clinic, Rochester, MI, USA.

Publikováno v: Lancet (London, England) [Lancet] 2017 Feb 04; Vol. 389 (10068), pp. 519-527. Date of Electronic Publication: 2016 Dec 23.

Clinical Profile and Treatment of Multiple Myeloma at a Tertiary Hospital in Kenya: A Five-Year Retrospective Review.

Autor: Gichuru, Wanjiku¹ (AUTHOR), Abinya, Nicholas A. O.² (AUTHOR), Odhiambo, Andrew¹ (AUTHOR), Otieno, Fredrick C. F.¹ (AUTHOR), Harrison, Simon³ (AUTHOR), Ong'ondi, Matilda⁴ (AUTHOR)

Publikováno v: Advances in Hematology. 2/12/2024, Vol. 2024, p1-6. 6p.

Imatinib mesylate associated with delayed hematopoietic recovery after concomitant chemotherapy.

Autor: Chand, M.¹, Thakuri, M.¹, Keung, Y-K¹ ykeung@wfubmc.edu

Publikováno v: Leukemia (08876924). Apr2004, Vol. 18 Issue 4, p886-887. 2p.